Complex immune-mediated conditions such as granulomatosis with polyangiitis, systemic lupus erythematosus, and rheumatoid lung disease fall under autoimmune/vasculitic lung disease. These disorders present diverse pulmonary manifestations, from interstitial involvement and nodules to diffuse alveolar hemorrhage. Timely recognition and immunosuppressive therapy are critical in preventing irreversible lung damage. Diagnostic approaches often rely on high-resolution CT, bronchoscopy, and serologic panels to distinguish overlapping pathologies. Autoimmune/vasculitic lung disease also highlights the role of biologics, including B-cell depleting agents and JAK inhibitors, in targeting inflammatory cascades. Managing these patients requires a careful balance between infection risk and immunomodulation. Integrating rheumatologic expertise and pulmonary rehabilitation into long-term care frameworks is essential to preserve function and improve prognosis.
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Non-canonical IRF3 functions in limiting pulmonary inflammation
Saurabh Chattopadhyay, University of Kentucky, United States
Title : New mechanisms and innovative therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : The representational challenge for designing and managing intelligent and ethical 5P medicine pulmonary, respiratory and lung health care systems
Habil Bernd Blobel, University of Regensburg, Germany
Title : From Chronic Obstructive Pulmonary Disease (COPD) to Non-Small Cell Lung Cancer (NSCLC): T helper cell epigenetic modifications and cancer risk
Koustav Sarkar, SRM Institute of Science and Technology, India
Title : Bacterial profile of community acquired pneumonia in a public health institute
Sayan Bhattacharyya, AIIH&PH, India